A new route to 3-(4-arylmethylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-one 9 was developed in six steps from commercial 1,4-diaminobutane 1 as starting material. The key step of this multi-step synthesis involved a solution phase "one-pot
Introduction
During the last decades, the five-membered heterocycle rings (FMHRs) are considered "privileged scaffolds" in medicinal chemistry [1] . Among the five-membered heterocycle rings, the 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones or 5-arylidene rhodanine derivatives represented particularly privileged moieties in drug discovery because they have an inherent tendency for biological activity [2] , such as DDX3 inhibitor for HIV replication [3] , as potent and selective inhibitors of the "atypical" dual-specificity phosphatase (DSP) family member-JNK-stimulating phosphatase-1 (JSP-1) [4] , as pancreatic cholesterol esterase (CEase) inhibitor [5] with IC50 values ranging from 1.44 to 85 μM. To discover chemical probes to further understand the function of human DNA polymerase λ in cancer, an inhibitor high-throughput screening (HTS) using SYBR ® Green-base assay [6] revealed that three 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones were identified as strong inhibitors. A new series of D-glutamic acid-base Escherichia coli MurD inhibitors incorporating the 5-arylidene rhodanine scaffold have been designed, synthesized and evaluated [7] . Substituted 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones were able to inhibit HIV replication in MT-4 cells at low micromolar concentration with an appreciable selectivity index and are good scaffolds for the development of novel HIV-1 integrase inhibitors [8] . Recently, a family of 5-arylalkylidene rhodanine derivatives presented antiviral activity against chikungunya virus (LR2006_OPY1) in Vero cell culture by cytopathic effect CPE reduction assay [9] . For Alzheimer's disease, the FMHRs derived from 5-arylidene-2-thioxo-1,3-thiazolidine-4-ones have been described for amyloid polypeptide fibril formation [10] , regulation of Cathepsin D immuno-reactivity in the senile plaques [11] and inhibition of tau aggregation [12] .
Protein kinases represent an important class of enzymes that play an important role in the regulation of various processes. These enzymes catalyze protein-phosphorylation on serine, threonine and tyrosine residues, which are frequently deregulated in human diseases. Only the 518 human kinases have been investigated as potential therapeutic targets [13] . Consequently, the search of protein-kinase inhibitors represented interesting targets in the pharmaceutical industry for new therapeutic agents. Over the past decade, our research group have investigated the chemical development of five-membered heterocycle rings derived from marine alkaloid as low-molecular weight-inhibitors of dual specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and CLKs (cdc2-like kinases) [14] [15] [16] , two families of kinases involved in various diseases including Alzheimer's disease (AD) [17] , and also cancer [18] [19] [20] .
Continuing in the effort to identify new DYRK inhibitors, particularly DYRK1A, we continued to explore successively the synthesis of N,Nʹ-bis- ( [22] and finally unsymmetrical linked bis-5-arylidene-rhodanine derivatives linked in N-3 position [23] as potential kinases inhibitors (Figure 1 ). Among the three series of symmetrical or unsymmetrical N,Nʹ-diamines bearing various platforms (imidazolidine-4-one or 2-thioxo-1,3-thiazolidine-4-one moieties), only one of these compounds has shown nanomolar inhibition potency (IC50 40 nM) towards DYRK1A. Owing to the fact that none of the unsymmetrical linked bis-5-arylidene rhodanines presented a significant activity against representative tumoral cell lines, we decided to change one of the two heterocyclic platforms by various (arylmethyl)aminobutyl moieties grafted on N-3 position of 5-arylidene-rhodanine derivatives in order to obtain significant potential biological activities on tumoral cell lines and effects on some protein kinases (HsCDK5-p25, SsGSK3α/β, SsCK1 and HsHaspin). Herein, we present the building of this 3-(4-arylmethylamino)butyl-5-arylidene-rhodanine library in which the 5-arylidene-2-thioxo-1,3-thiazolidine-4-one moiety was mostly carried out under microwave irradiation [24] and the biological activities of these compounds. 
5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl) diamines [21], N,Nʹ-bis-(5-arylidene-4-oxo-4,5-dihydrothiazolidine-2-yl)aminopropylpiperazines

Results and Discussion
Chemistry
Access to the planned 3-(4-arylphenylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9 is outlined in Scheme 1. For this study, we selected a diamino linker 1 with a butyl chain in order to obtain a good molecular flexibility between the 4-arylmethyl moiety and the 2-thioxo-1,3-thiazolidine-4-one platform. A molecule with the lowest number of carbons for the diamino linker is more conformationally restrained [25] . The 1,4-diamino-butane linker 1 was treated with di-tert-butyldicarbonate (Boc2O) in 1,4-dioxane at room temperature to afford mainly the mono-N-Boc protected amine 2 in good yield (84%) [26] . To obtain a sufficient number of compounds suitable for a preliminary biological screening, we privileged the transformation of N-Boc-1,4-diamino-butane 2 into mono protected N-arylmethyl diamine 5 by reductive amination in two steps. The (4-arylmethylamino)butyl chain appended on the N-3 position of the 2-thioxo-1,3-thiazolidine-4-one platform represent the first point of diversity for the desired target compounds 9. Preparation of 4 was easily realized by reaction between of appropriate arylaldehyde 3a-f with N-Boc diamine 2 in the presence of molecular sieves 3Å and, the condensation was conducted in a solution of diethyl ether Et2O at room temperature during 24 h. Then, transformation of arylaldimines 4 into mono protected N-arylmethyl diamines 5 could be readily accomplished in good yields (85% to 98%) using NaBH4 (5 equiv.) in MeOH at 50 °C during 24 h. For the cleavage of N-Boc group, the use of trifluoroacetic acid in dichloromethane is often efficient, but in our case, we observed the formation of impurities resulting from uncontrolled degradation of 5 in this strong acidic media. We thus preferred to use a more classical and practical approach by using a solution of 6M HCl. The deprotection was conducted in 1,4-dioxane at room temperature after 4 h of reaction time. As can be seen from the data presented in Table 1 , the N-(arylmethyl)butane-1,4-diamine hydrochloride 6a-f were efficiently prepared with electron-rich and electron-poor aldehydes 3a-f in yields ranging from 72% to 98%.
Route used for the preparation of 3-(4-arylphenylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9 via the "one-pot two-steps" reaction under microwave. With the desired salts 6 in hand, we wished to examine the construction of the 2-thioxo-1,3-thiazolidine-4-one platform followed by Knoevenagel condensation using arylaldehyde 3 under microwave irradiation for installation of the 5-arylidene moiety. The choice of arylaldehydes 3 in Knoevenagel condensation represent, in fact, the second point of diversity in the final structure of the targeted compounds 9. In a previous work issued from our laboratory [23] , we have developed a "one-pot two-steps" method under microwave irradiation, which was applied for the synthesis of unsymmetrical linked bis-arylidene rhodanines from symmetric diamines. ----84  4a  3a  ----97  4b  3b  ----99  4c  3c  ----98  4d  3d  ----98  4e 3e -97  6c  5c  ----98  6d  5d  ----98  6e  5e  ----72  6f  5f  ----92  9a  3e  6b  3  30  30  10  9b  3b  6b  3  30  30  6  9c  3f  6b  3  30  30  5  9d  3g  6b  3  30  30  30  9e  3e  6d  3  15  15  21  9f  3f  6d  3  15  15  9  9g  3d  6d  3  30  30  5  9h  3e  6e  2  15  15  59  9i  3f  6e  2  15  15  59  9j  3h  6e  2  15  15  34  9k  3g  6e  3  30  30  46  9l  3e  6f  3  15  15  15  9m  3f  6f  3  15  15  7  9n  3g  6f  3  30  30 34
a Reaction realized in a tube (sealed with a snap cap) under microwave irradiation (μω) with the Monowave N-(arylmethyl)butane-1,4-diamine hydrochloride 6 to afford the intermediate 8 and secondly, Knoevenagel condensation to produce the desired 5-arylidene rhodanines 9. This "one-pot two-steps" methodology was realized under microwave dielectric heating because the use of commercial scientific laboratory microwave apparatus favoured higher product yields and significant rate enhancements compared to reactions which run with conventional heating (i.e., in oil bath) [27] . After several experiments, optimal reaction conditions for this "one-pot two-steps" synthesis involved reaction of a stoichiometric mixture of N-(arylmethyl)butane-1,4-diamine hydrochloride 6 and commercial reagent 7 solubilized in dimethoxyethane with one or two equivalents of triethylamine. This starting reaction mixture was placed in a commercial glass tube closed with a snap cap and was irradiated with appropriate reaction time (15 or 30 min.) at 90 °C. After this first period of microwave irradiation followed by a cooling down to room temperature, aromatic aldehyde 3 was directly added to the crude suspension and was submitted again to microwave dielectric heating at 110 °C during 15 or 30 min for condensation.
The desired compound 9 was obtained as precipitate after addition of methanol in the solventless crude reaction mixture (after elimination of the volatile compounds in vacuo) and triturated, followed by successive washings with deionized water, ethanol, ether and finally was recrystallized from absolute EtOH to increase the quality of the precipitated product 9. A set of 14 pure compounds 9a-n was prepared in 5%-59% yield (Table 1 ) and all the products 9 were characterized by 1 H-, 13 C-NMR and HRMS before entering the biological tests. For the exocyclic double bond (CH=C) in C-5 position of all the 3-(4-arylmethylamino)butyl-2-thioxo-1,3-thiazolidine-4-one 9a-n, it's possible in theory to observe E-and/or Z-geometrical isomers. Examination of their 1 H-NMR spectra in DMSO-d6 showed only one signal for the methylene proton (CH=) in the range 7.54-7.74 ppm at lower field values than those expected for the E-isomers, which indicates that all the compounds 9a-n have the Z-configuration due to the high degree of thermodynamic stability of this isomer [28, 29] . In 13 C-NMR, the signal of C-5 (C=) appears in the range 120.0-127.5 ppm, and we also observed only one signal for the exocyclic methylene proton (134.6 < δCH= < 135.9 ppm) that confirmed the presence of only the Z-geometrical isomer for the targeted compounds 9a-n.
Biology
As an initial effort to investigate their in vitro bioactivity, the new synthesized 3-(4-arylmethylamino) butyl-2-thioxo-1,3-thiazolidine-4-one 9a-n and also their precursors 6a-f were evaluated for their in vitro inhibition of cell proliferation. For this study, we used a panel of seven representative tumoral cell lines, namely HuH7 D12 (differential hepato cellular carcinoma), Caco 2 (differentiating colorectal adenocarcinoma), MDA-MBD231 (prostate carcinoma), HCT 116 (actively proliferating colorectal adenocarcinoma), PC3 (prostate carcinoma), NCI-H727 (lung carcinoma), HaCat keratinocyte and, diploid skin fibroblasts as normal cell lines for control. Roscovitine, Doxorubicine and Taxol were also used as positive controls and their IC50 values are compared with those obtained for compounds 6 and 9. Results of the in vitro antiproliferative data activity are reported in Table 2 . None of the N-(arylmethyl) butane-1,4-diamines hydrochloride 6a-f presented a significant activity against the seven representative tumoral cell lines. For the other compounds 9, the most active compound was clearly 9i (Figure 2 ) and exhibited antitumor activities in the HuH7 D12, MDA-MBD231 and HaCat cell lines with IC50 values lower than 10 μM (HuH7 D12 and MDA-MBD231: IC50 9 μM) and did not inhibit the growth of normal fibroblasts (IC50 > 25 μM). In addition, compounds 9d, 9h, 9j and 9n presented moderate antitumor activities (IC50 10-17 μM) in all cell lines of the panel but without selectivity. (10) 23 (15) 15 (11) 1 (10) 41 (17) 11 (10) 2 (10) (14) 49 (10) 65 (13) 51 (13) 43 (>25) 10 (10) 80 (>25) 9i 5 (9) 17 (13) 17 (9) 8 (14) 39 (14) 9 (11) 6 (8) IC 50 values in brackets are expressed in μM and are the average of three assays, standard error ± 0.5 μM. Then, we evaluated the intermediates salts 6a-f and fourteen final compounds 9a-n on four protein kinases: HsCDK5-p25 (cyclin-dependant kinase 5-p25), SsGSK-3α/β (glycogen synthase kinase-3α/β) SsCK1δ/ε (Caseine kinase 1) and HsHaspin as an essential mitotic kinase [30] . All assays were run in the presence of 15 μM of ATP and appropriate substrates. IC50 values were determined from dose-response curves. Concerning the library of the fourteen (5Z) 3-(4-arylmethylamino)butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9a-n and also the six diamines salts 6a-f, the results are given in Table 3 . Among all the products, the main part of their inhibition activity was focused on two proteins kinases (SsCK1 and HsCDK5-p25) for four products, which exhibited inhibitory activity in the micromolar range (SsCK1: 1.4 μM < IC50 < 6.6 μM; HsCDK5-p25: IC50 1.2 μM). For the compound 9j and 9n, we observed micromolar inhibition activity on SsCK1 (IC50 values for 9j: 1.4 μM and 9n: 2 μM) with good selectivity. It is interesting to note that these two compounds are respectively substituted with an hydroxyl function on para-position of the 5-arylidene moiety and also with a similar bulky group (1,3-benzodioxol-5-yl for 9j and 2,3-dihydro-benzo [1, 4] dioxin-6-yl for 9n) on the arylmethylamino moiety grafted on the N-3 butyl chain. On the contrary, the presence of 1,3-benzodioxol-5-yl (for 9h) or 2,3-dihydro-benzo [1, 4] dioxin-6-yl moiety (for 9i) in the 5-arylidene group induced a moderate loss of inhibition activity for SsCK1 (IC50 for 9h: 6.6 μM and 9i: 5.4 μM) associated with micromolar affinity for HsCDK5-p25 (IC50 for 9h: 1.1 μM and 9i: 1.3 μM). Compound 9i presented also inhibition proliferation activity on Huh7 D12, MDA-MBD231 cell lines and is inactive against normal fibroblasts. Table 3 . Effects of the compounds 6a-f and 9a-n on the catalytic activity of four purified protein kinases a .
Compound
HsCDK5/p25 SsGSK-3α/β SsCK1δ/ε HsHaspin
Note:
a Compounds were tested at various concentrations on each kinase as described in Experimental Section. IC 50 values, calculated from the dose-response curves, are reported in μM > 10, inhibitory but IC 50 > 10 μM.
Experimental Section
Chemistry Section
General Section
Melting points were determined on a Kofler melting point apparatus and were uncorrected. Thin-layer chromatography (TLC) was accomplished on 0.2-mm precoated plates of silica gel 60 F-254 (Merck, Fontenay-sous-Bois, France). Visualization was made with ultraviolet light (254 and 365 nm) or with a fluorescence indicator. 1 H-NMR spectra were recorded on BRUKER AC 300 P (300 MHz) spectrometer, 13 C-NMR spectra on a BRUKER AC 300 P (75 MHz) spectrometer. Chemical shifts are expressed in parts per million downfield from tetramethylsilane as an internal standard. Data are given in the following order: δ value, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad), number of protons, coupling constants J is given in Hertz. The mass spectra (HRMS) were taken respectively on a MS/MS ZABSpec Tof Micromass (EBE TOF geometry) at an ionizing potential of 8 eV and on a VARIAN MAT 311 at an ionizing potential of 70 eV in the Centre Régional de Mesures Physiques de l'Ouest (CRMPO, Rennes, France). Reactions under microwave irradiations were realized in the Anton Paar Monowave 300 ® microwave reactor (Anton-Paar, Courtaboeuf, France) using borosilicate glass vials of 10 mL equipped with snap caps (at the end of the irradiation, cooling reaction was realized by compressed air). The microwave instrument consists of a continuous focused microwave power output from 0 to 800 W for this Monowave 300 ® apparatus. All the experiments in the microwave reactor were performed using a stirring option. The target temperature was reached with a ramp of 5 min and the chosen microwave power stayed constant to hold the mixture at this temperature. The reaction temperature is monitored using calibrated infrared sensor and the reaction time included the ramp period. The microwave irradiation parameters (power and temperature) were monitored by the Monowave software package of the Monowave 300 ® microwave reactor. Solvents were evaporated with a BUCHI rotary evaporator. All reagents and solvents were purchased from Acros, Sigma-Aldrich Chimie (Saint-Quentin Fallavier, France), TCI France and Fluka France and were used without further purification. (2) . In a 250 mL two-necked round-bottomed flask, provided with magnetic stirrer and condenser, commercial 1,4-diaminobutane 1 (14.3 mL, 12.5 g, 0.14 mol) was solubilized in 69 mL of 1,4-dioxane at room temperature. To this mixture was added dropwise a solution of commercial di-tert-butyldicarbonate (6.5 g, 30 mmol) in 1,4-dioxane (85 mL) over a period of 3 h. After vigorous stirring at 25 °C during a 12 h period, the volatile compounds of the reaction mixture were eliminated in vacuo and into the crude reaction mixture was poured 150 mL of deionized water. The mixture was extracted with methylene chloride (5 × 50 mL), organic phases were collected and dried over magnesium sulfate. The filtrate was concentrated in a rotary evaporator under reduced pressure and was dried under high vacuum (10
tert-Butyl (4-aminobutyl)carbamate
Torr) at 25 °C for 10 min. The desired carbamate 2 (1.58 g) was obtained as a colourless mobile oil in 84% yield and was further used without purification. In a 100 mL two-necked round-bottomed flask, provided with magnetic stirrer and condenser, containing a solution of tert-butyl (4-aminobutyl)carbamate 2 (1.97 g, 10.5 mmol) in anhydrous ether (50 mL) was added dropwise during 30 min, a suspension of commercial aldehyde (10 mmol) in anhydrous ether (30 mL) and molecular sieves (2 g, 3 Å, 8-12 mesh). The crude reaction mixture is stirred vigorously for 16 h at room temperature until the disappearance of aromatic aldehyde 3 controlled by thin-layer chromatography on 0.2-mm precoated plates of silica gel 60 F-254 (Merck). The crude reaction mixture was filtered on filter paper and then concentrated in a rotary evaporator under reduced pressure. The crude residue was dried under high vacuum (10 
{4-[(4-Methoxy-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester (4b)
. Compound 4b was prepared in 99% yield (3.03 g) from 4-methoxybenzaldehyde 3b (1.36 g, 10 mmol) according to the standard procedure as yellowish viscous oil.
{4-[(3-Methoxy-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester (4d).
Compound 4d was prepared in 98% yield (3.03 g) from 3-methoxybenzaldehyde 3d (1.36 g, 10 mmol) according to the standard procedure as yellowish viscous oil. [1, 3] 
{4-[(Benzo
{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-amino]-butyl}-carbamic acid tert-butylester (4f)
. Compound 4f was prepared in 99% yield (3.31 g) from 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 3f (1.50 g, 10 mmol) according to the standard procedure as yellowish viscous oil.
Standard Procedure for Reduction of Aldimines 4a-f into N-Boc Monoprotected Diamines 5a-f
In a 50 mL two-necked round-bottomed flask, provided with a magnetic stirrer and reflux condenser, compound 4 (5 mmol) was dissolved in methanol p.a. (30 mL) under vigorous stirring and cooled at 0 °C. To this solution was added by small portions commercial sodium borohydride NaBH4 (0.95 g, 25 mmol) over a period of 20 min. The resulting suspension was stirred at 50 °C for 24 h (monitored by TLC on 0.2-mm precoated plates of silica gel 60 F-254, Merck). After cooling down to room temperature, the volatile compounds were removed in a rotary evaporator under reduced pressure, then deionized water (40 mL) was added in one portion to the crude residue. The mixture was transferred to a separating funnel and was extracted with dichloromethane (3 × 50 mL). The combined organic phases were dried over magnesium sulphate MgSO4, filtered on filter paper and the solvent was eliminated in vacuo. The crude residue was dried under high vacuum (10 −2 Torr) at 25 °C for 2 h. The desired compound 5 was obtained as yellowish viscous oil and was further used without purification.
(4-Phenylmethylamino-butyl)-carbamic acid tert-butyl ester (5a).
Compound 5a was prepared in 93% yield (1.25 g) from [4-(benzylidene-amino)-butyl]-carbamic acid tert-butyl ester 4a (1.38 g, 5 mmol) according to the standard procedure that gave 5a as yellowish viscous oil. 
[4-(4-Methoxy-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5b
[4-(2-Chloro-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5c).
Compound 5c was prepared in 85% yield (1.33 g) from {4-[(2-chloro-benzylidene)-amino]-butyl}-carbamic acid tert-butyl ester 4c (1.55 g, 5 mmol) according to the standard procedure that gave 5c as yellowish viscous oil. 
[4-(3-Methoxy-phenylmethylamino)-butyl]-carbamic acid tert-butyl ester (5d). Compound 5d was prepared in 90% yield (1.39 g) from {4-[(3-methoxy-benzylidene)-amino]-butyl}-carbamic acid
tert-butyl ester 4d (1.53 g, 5 mmol) according to the standard procedure that gave 5d as pale pink viscous oil. 
{4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-butyl}-carbamic acid tert-butyl ester (5e).
Compound 5e was prepared in 97% yield (1.56 g) from {4-[(benzo [1, 3] dioxol-5-ylmethylene)-amino]-butyl}-carbamic acid tert-butyl ester 4e (1.60 g, 5 mmol) according to the standard procedure that gave 5e as yellowish viscous oil. 
{4-[(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethyl)-amino]-butyl}-carbamic acid tert-butyl ester (5f).
Compound 5f was prepared in 88% yield (1.48 g) from {4-[(2,3-dihydro-benzo [1, 4] dioxin-6-ylmethylene)-amino]-butyl}-carbamic acid tert-butylester 4f (1.67 g, 5 mmol) according to the standard procedure that gave 5f as yellowish viscous oil. In a 100 mL two-necked round-bottomed flask provided with a magnetic stirrer and condenser, N-Boc monoprotected diamine 5 (12.1 mmol, 1 equiv.) was solubilized in 1,4-dioxane (80 mL) at room temperature under vigorous stirring for 10 min. To this homogeneous solution was added dropwise for 1 h a solution of 6 M HCl (20 mL). The reaction mixture was stirred during 4 h at 25 °C and was concentrated in a rotary evaporator under reduced pressure for elimination of volatile compounds. To the crystallized crude reaction mixture was added 60 mL of anhydrous Et2O and after triturating, the insoluble salt 6 was collected by filtration, on a Büchner funnel (porosity N°4) then washed with 6 × 10 mL of Et2O. The desired salt 6 was dried under high vacuum (10
Torr) at 25 °C for 1 h that gave a yellowish or white powder and was further used without purification.
N-1-Phenylmethyl-butane-1,4-diamine hydrochloride (6a).
Compound 6a was prepared in 84% yield (2.18 g) from (4-phenylmethylamino-butyl)-carbamic acid tert-butyl ester 5a (3.37 g, 12.1 mmol) according to the standard procedure as yellowish powder. Mp > 260 °C. 
N-1-(4-Methoxy-phenylmethyl)-butane1,4-diamine hydrochloride (6b).
Compound 6b was prepared in 97% yield (2.87 g) from (4-methoxyphenylmethylamino-butyl)-carbamic acid tert-butyl ester 5b (3.73 g, 12.1 mmol) according to the standard procedure as pale brownish powder. Mp > 260 °C. In a 10 mL glass tube were placed successively bis-(carboxymethyl)trithiocarbonate 7 (0.11 g, 0.50 mol, 1 equiv.), dimethoxyethane (2 mL), triethylamine (135 mL, 101 mg, 1 mmol, 2 equiv. or 202 mL, 152 mg, 1.5 mmol, 3 equiv.) and hydrochloride salt 6 (0.5 mmol, 1 equiv.). The glass tube was sealed with a snap cap and placed in the Monowave ® 300 Anton Paar microwave cavity (p = 800 Watt). The reaction mixture was irradiated at 90 °C for 15-60 min. under vigorous magnetic stirring. After microwave dielectric heating, the crude reaction mixture was allowed to cool down at room temperature, aldehyde 3 (0.5 mol, 1 equiv.) was added to the cooled reaction mixture which was immediately submitted to microwave irradiation at 110 °C for 5-30 min. After cooling down to room temperature, the volatile compounds of the reaction mixture were removed in a rotary evaporator under reduced pressure. To the crude reaction mixture was added 4 mL of MeOH and after triturating, the insoluble product 9 was collected by filtration on a Büchner funnel (porosity N°4), washed with deionized water (5 mL), triturated and mixing with ethanol (3 × 5 mL) during 3 h, washed successively with ethanol (5 mL) and anhydrous ether (5 × 2 mL), then dried under high vacuum (10
N-1-(3-Methoxy-phenylmethyl)-butane-1,4-diamine hydrochloride (6d
Torr) at 25 °C for 1 h. The desired compound 9 was eventually purified by recrystallization in EtOH after control by 1 H-NMR in solution of CDCl3/TFA (98:2). (1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3 thiazolidin-4-one (9a). According to the standard procedure, compound 9a was prepared in 10% yield (23 mg ) from N-1-(4-methoxy-phenylmethyl)-butane-1,4 -diamine hydrochloride 6b (122.3 mg, 0.5 mmol, 1 equiv.), triethylamine (202 μL, 152 mg, 1.5 mmol, 3 equiv.) and piperonaldehyde 3e (75.1 mg, 0.5 mmol, 1 equiv.) after 30 min. at 90 °C, followed by a second reaction time of 30 min. at 110 °C (for condensation step with 3e), which gave 9a as a yellowish powder. Mp = 170-229 °C (decomposition). 
(5Z)3-[4-(4-Methoxyphenylmethylamino)butyl]-5-
Conclusions
In summary, we have developed, in this preliminary project, a new route to (5Z) 3-(4-arylmethylamino) butyl-5-arylidene-2-thioxo-1,3-thiazolidine-4-ones 9. Starting from commercial butane-1,4-diamine, the process involved six steps and the key step is a solution phase "one-pot two-steps" approach for the construction of the 2-thioxo-1,3-thiazolidine-4-one platform under microwave dielectric heating followed by Knoevenagel condensation for installation of the 5-arylidene moiety as second point of diversity. This methodology offered the possibility of preparing a library of fourteen new compounds in moderate to good yields and, the targeted compounds 9a-n have been built with a Z-geometry. The in vitro inhibition of cell proliferation was carried out on a panel of seven representative tumoral cell lines and the compounds 9a-n were also evaluated against four protein kinases. Among all of these compounds, the compound 9j turned out to be interesting because it presented selective micromolar inhibition activity on SsCK1 (IC50 1.4 μM). Molecules 9h and 9i were also bioactive on SsCK1 and HsCDK5-p25. The current results are the starting point of a new larger program within our group to investigate intensively the biological properties of these new inhibitors with potential application in Alzheimer's disease or in cancer.
